Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...
BioPharma Dive12d
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.
MedCity News10d
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...
MarketWatch on MSN11d
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings ...
FierceBiotech11d
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
Metsera, Inc IPOs Tomorrow, Here's What You Need To Know
Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...
pharmaphorum11d
Two more biotechs, Metsera and Maze, cross IPO finish line
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
Seeking Alpha on MSN11d
Metsera sees stock rally 54% following $275M IPO
Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.
Nasdaq12d
Metsera, Inc. Prices Initial Public Offering at $18.00 per Share, Aiming for $275 Million Gross Proceeds
Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...